Meanwhile, the BSE Sensex was up 93.29 points, or 0.33%, to 28,562.04.

On the BSE, so far 85.26 lakh shares were traded in the counter, compared with average daily volumes of 3.66 lakh shares in the past one quarter. The stock had hit a high of Rs 48.70 and a low of Rs 41.65 so far during the day.

The stock hit a 52-week high of Rs 58.30 on 4 October 2016. The stock hit a 52-week low of Rs 33.45 on 1 March 2016. The stock had underperformed the market over the past 30 days till 17 February 2017, rising 2.27% compared with the 4.25% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 5.03% as against Sensex's 8.87% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Re 1.

Marksans Pharma said that its plant located at L-82 and L-83, Verna Industrial Estate, Verna, Goa - 403 722 has had an inspection by UK Medicines and Healthcare products Regulatory Agency (UK MHRA) from 14 February 2017 to 17 February 2017. The same has been completed without any critical observations. The company is awaiting further instruction from the agency in this regard.

On a consolidated basis, net profit of Marksans Pharma declined 36.98% to Rs 11.30 crore on 1% decline in net sales to Rs 215.24 crore in Q3 December 2016 over Q3 December 2015.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.